The truncated ghrelin receptor polypeptide (GHS-R1b) is localized in the endoplasmic reticulum where it forms heterodimers with ghrelin receptors (GHS-R1a) to attenuate their cell surface expression

Molecular and Cellular Endocrinology

Volumn 348, Issue 1, 2012, Pages 247-254

  Chow, Kevin B S ^a   Sun, Jingxin ^a   Man Chu, Kit ^a   Tai Cheung, Wing ^a   Cheng, Christopher H K ^a   Wise, Helen ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

ANOVA; BRET; Dominant negative mutant; ER; ERK1 2; Ghrelin receptor; GHS; GHS R1b; Heterodimerization

Indexed keywords

GHRELIN RECEPTOR; HETERODIMER; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOLIPASE C; TRUNCATED GHRELIN RECEPTOR POLYPEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; CELL MEMBRANE; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EMBRYO; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

EID: 80755132266     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.08.034     Document Type: Article

References (54)

1. Angers S., Salahpour A., Bouvier M. Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annu. Rev. Pharmacol. Toxicol. 2002, 42:409-435.
2. Ayoub M.A., Pfleger K.D. Recent advances in bioluminescence resonance energy transfer technologies to study GPCR heteromerization. Curr. Opin. Pharmacol. 2010, 10:44-52.
3. Benkirane M., Jin D.Y., Chun R.F., Koup R.A., Jeang K.T. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by cc5D32. J. Biol. Chem. 1997, 272:30603-30606.
4. Calebiro D., Nikolaev V.O., Persani L., Lohse M.J. Signaling by internalized G-protein-coupled receptors. Trends Pharmacol. Sci. 2010, 31:221-228.
5. Camina J.P., Lodeiro M., Ischenko O., Martini A.C., Casanueva F.F. Stimulation by ghrelin of p42/p44 nitrogen-activated protein kinase through the GHS-R1a receptor: role of G-proteins and b-arrestins. J. Cell. Physiol. 2007, 213:187-200.
6. Casar B., Arozarena I., Sanz-Moreno V., Pinto A., Agudo-Ibáñez L., Marais R., Lewis R.E., Berciano M.T., Crespo P. Ras subcellular localization defines extracellular signal-regulated kinase 1 and 2 substrate specificity through distinct utilization of scaffold proteins. Mol. Cell. Biol. 2009, 29:1338-1353.
7. Chan C.B., Cheng C.H.K. Identification and functional characterization of two alternatively spliced growth hormone secretagogue receptor transcripts from the pituitary of black seabream Acanthopagrus schlegeli. Mol. Cell. Endocrinol. 2004, 214:81-95.
8. Chow K.B.S., Cheng C.H.K., Wise H. Anti-inflammatory activity of ghrelin in human carotid artery cells. Inflammation 2009, 32:402-409.
9. Chow K.B.S., Leung P.K., Cheng C.H.K., Cheung W.T., Wise H. The constitutive activity of ghrelin receptors is decreased by co-expression with vasoactive prostanoid receptors when over-expressed in human embryonic kidney 293 cells. Int. J. Biochem. Cell Biol. 2008, 40:2627-2637.
10. Christophe D., Christophe-Hobertus C., Pichon B. Nuclear targeting of proteins: how many different signals?. Cell. Signal. 2000, 12:337-341.
11. Chu K.M., Chow K.B.S., Leung P.K., Lau P.N., Chan C.B., Cheng C.H.K., Wise H. Over-expression of the truncated ghrelin receptor polypeptide attenuates the constitutive activation of phosphatidylinositol-specific phospholipase C by ghrelin receptors but has no effect on ghrelin-stimulated extracellular signal-regulated kinase 1/2 activity. Int. J. Biochem. Cell Biol. 2007, 39:752-764.
12. 1A-adrenoceptors. Biochem. J. 1999, 343:231-239.
13. Ding W.Q., Cheng Z.J., McElhiney J., Kuntz S.M., Miller L.J. Silencing of secretin receptor function by dimerization with a misspliced variant secretin receptor in ductal pancreatic adenocarcinoma. Cancer Res. 2002, 62:5223-5229.
14. Du Y., Ferro-Novick S., Novick P. Dynamics and inheritance of the endoplasmic reticulum. J. Cell Sci. 2004, 117:2871-2878.
15. Elmhurst J.L., Xie Z., O'Dowd B.F., George S.R. The splice variant D3nf reduces ligand binding to the D3 dopamine receptor: evidence for heterooligomerization. Mol. Brain Res. 2000, 80:63-74.
16. Galés C., Rebois R.V., Hogue M., Trieu P., Breit A., Hébert T.E., Bouvier M. Real-time monitoring of receptor and G-protein interactions in living cells. Nat. Methods 2005, 2:177-184.
17. Gnanapavan S., Kola B., Bustin S.A., Morris D.G., McGee P., Fairclough P., Bhattacharya S., Carpenter R., Grossman A.B., Korbonits M. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J. Clin. Endocrinol. Metab. 2002, 87:2988-2991.
18. Gobeil F., Fortier A., Zhu T., Bossolasco M., Leduc M., Grandbois M., Heveker N., Bkaily G., Chemtob S., Barbaz D. G-protein-coupled receptors signalling at the cell nucleus: an emerging paradigm. Can. J. Physiol. Pharmacol. 2006, 84:287-297.
19. Grosse R., Schöneberg T., Schultz G., Gudermann T. Inhibition of gonandotropin-releasing hormone receptor signaling by expression of a splice variant of the human receptor. Mol. Endocrinol. 1997, 11:1305-1318.
20. Guan R., Feng X., Wu X., Zhang M., Zhang X., Hébert T.E., Segaloff D.L. Bioluminescence resonance energy transfer studies reveal constitutive dimerization of the human lutropin receptor and a lack of correlation between receptor activation and the propensity for dimerization. J. Biol. Chem. 2009, 284:7483-7494.
21. Holliday N.D., Holst B., Rodionova E.A., Schwartz T.W., Cox H.M. Importance of constitutive activity and arrestin independent mechanisms for intracellular trafficking of the ghrelin receptor. Mol. Endocrinol. 2007, 21:3100-3112.
22. Holst B., Cygankiewicz A., Jensen T.H., Ankersen M., Schwartz T.W. High constitutive signaling of the ghrelin receptor - identification of a potent inverse agonist. Mol. Endocrinol. 2003, 17:2201-2210.
23. Howard A.D., Feighner S.D., Cully D.F., Arena J.P., Liberator P.A., Rosenblum C.I., Hamelin M., Hreniuk D.L., Palyha O.C., Anderson J., Paress P.S., Diaz C., Chou M., Liu L.-Y., McKee K.K., Pong S.-S., Chaung L.-Y., Elbrecht A., Dashkevicz M., Heavens R., Rigby M., Sirinathsinghji D.J.S., Dean D.C., Melillo D.G., Patchett A.A., Nargund R., Griffin P.R., DeMartino J.A., Gupta S.K., Schaeffer J.M., Smith R.G., Van der Ploeg L.H.T. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996, 273:974-977.
24. Ibrahim S., Tetruashvily M., Frey A.J., Wilson S.J., Stitham J., Hwa J., Smyth E.M. Dominant negative actions of human prostacyclin receptor variant through dimerization: implications for cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1802-1809.
25. James J.R., Oliveira M.I., Carmo A.M., Iaboni A., Davis S.J. A rigorous experimental framework for detecting protein oligomerization using bioluminescence resonance energy transfer. Nat. Methods 2006, 3:1001-1006.
26. Jia Y., Nguyen T., Desai M., Ross M.G. Programmed alterations in hypothalamic neuronal orexigenic responses to ghrelin following gestational nutrient restriction. Reprod. Sci. 2008, 15:702-709.
27. Karpa K.D., Lin R., Kabbani N., Levenson R. The dopamine D3 receptor interacts with itself and the truncated D3 splice variant D3nf: D3-D3nf interaction causes mislocalization of D3 receptors. Mol. Pharmacol. 2000, 58:677-683.
28. Kern A., Hubbard D., Amano A., Bryant-Greenwood G.D. Cloning, expression, and functional characterization of relaxin receptor (leucine-rich repeat-containing G protein-coupled receptor 7) splice variants from human fetal membranes. Endocrinology 2008, 149:1277-1294.
29. Kojima M., Kangawa K. Ghrelin: more than endogenous growth hormone secretagogue. Ann. N.Y. Acad. Sci. 2010, 1200:140-148.
30. Korbonits M., Bustin S.A., Kojima M., Jordan S., Adams E.F., Lowe D.G., Kangawa K., Grossman A.B. The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. J. Clin. Endocrinol. Metab. 2001, 86:881-887.
31. Kumar V., Jong Y.-J., O'Malley K.L. Activated nuclear metabotropic glutamate receptor mGlu5 couples to nuclear Gq/11 proteins to generate inositol 1,4,5-trisphosphate-mediated nuclear Ca2+ release. J. Biol. Chem. 2008, 283:14072-14083.
32. Lau P.N., Chow K.B., Chan C.B., Cheng C.H., Wise H. The constitutive activity of the ghrelin receptor attenuates apoptosis via a protein kinase C-dependent pathway. Mol. Cell. Endocrinol. 2009, 299:232-239.
33. Leung P.K., Chow K.B.S., Lau P.N., Chu K.M., Chan C.B., Cheng C.H.K., Wise H. The truncated ghrelin receptor polypeptide (GHS-R1b) acts as a dominant-negative mutant of the ghrelin receptor. Cell. Signal. 2007, 19:1011-1022.
34. Lohse M.J. Dimerization in GPCR mobility and signaling. Curr. Opin. Pharmacol. 2010, 10:53-58.
35. Maggio R., Novi F., Scarselli M., Corsini G.U. The impact of G-protein-coupled receptor hetero-oligomerization on function and pharmacology. FEBS J. 2005, 272:2939-2946.
36. 2-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer. J. Biol. Chem. 2002, 277:44925-44931.
37. Milligan G. G protein-coupled receptor dimerization: function and ligand pharmacology. Mol. Pharmacol. 2004, 66:1-7.
38. Milligan G. The role of dimerisation in the cellular trafficking of G-protein-coupled receptors. Curr. Opin. Pharmacol. 2010, 10:23-29.
39. 1 subtype. J. Biol. Chem. 1997, 271:31255-31261.
40. Pantel J., Legendre M., Cabrol S., Hilal L., Hajaji Y., Morisset S., Nivot S., Vie-Luton M.P., Grouselle D., de Kerdanet M., Kadiri A., Epelbaum J., Le Bouc Y., Amselem S. Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. J. Clin. Invest. 2006, 116:760-768.
41. Petersen P.S., Woldbye D.P.D., Madsen A.N., Egerod K.L., Jin C., Lang M., Rasmussen M., Beck-Sickinger A.G., Holst B. In vivo characterization of high basal signaling from the ghrelin receptor. Endocrinology 2009, 150:4920-4930.
42. Robben J.H., Kortenoeven M.L.A., Sze M., Yae C., Milligan G., Oorschot V.M., Klumperman J., Knoers N.V.A.M., Deen P.M.T. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists. Proc. Natl. Acad. Sci. 2009, 106:12195-12200.
43. Salahpour A., Angers S., Bouvier M. Functional significance of oligomerization of G-protein-coupled receptors. Trends Endocrinol. Metabol. 2000, 11:163-168.
44. Salahpour A., Angers S., Mercier J.F., Lagacé M., Marullo S., Bouvier M. Homodimerization of the b2-adrenergic receptor as a prerequisite for cell surface targeting. J. Biol. Chem. 2004, 279:33390-33397.
45. Sánchez-Laorden B.L., Herraiz C., Valencia J.C., Hearing V.J., Jiménez-Cervantes C., García-Borrón J.C. Aberrant trafficking of human melanocortin 1 receptor variants associated with red hair and skin cancer: steady-state retention of mutant forms in the proximal Golgi. J. Cell. Physiol. 2009, 220:640-654.
46. Smith R.G., Jiang H., Sun Y. Developments in ghrelin biology and potential clinical relevance. Trends Endocrinol. Metabol. 2005, 16:436-442.
47. Sun Y., Butte N.F., Garcia J.M., Smith R.G. Characterization of adult ghrelin and ghrelin receptor knockout mice under positive and negative energy balance. Endocrinology 2008, 149:843-850.
48. Takahashi K., Furukawa C., Takano A., Ishikawa N., Kato T., Hayama S., Suzuki C., Yasui W., Inai K., Sone S., Ito T., Nishimura F., Tsuchiya E., Nakamura Y., Daigo Y. The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. Cancer Res. 2006, 66:9408-9419.
49. Trettel F., Bartolomeo S., Lauro C., Catalano M., Ciotti M.T., Limatola C. Ligand-independent CXCR2 dimerization. J. Biol. Chem. 2003, 278:40980-40988.
50. van Rijn R.M., van Marle A., Chazot P.L., Langemeijer E., Qin Y., Shenton F.C., Lim H.D., Zuiderveld O.P., Sansuk K., Dy M., Smit M.J., Tensen C.P., Bakker R.A., Leurs R. Cloning and characterization of dominant negative splice variants of the human histamine H4 receptor. Biochem. J. 2008, 414:121-131.
51. Waseem T., Duxbury M., Ito H., Ashley S.W., Robinson M.K. Exogenous ghrelin modulates release of pro-inflammatory and anti-inflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways. Surgery 2008, 143:334-342.
52. Zhao T.-J., Liang G., Li R.L., Xie X., Sleeman M.W., Murphy A.J., Valenzuela D.M., Yancopoulos G.D., Goldstein J.L., Brown M.S. Ghrelin O-acetlytransferase (GOAT) is essential for growth hormone-mediated survival of calorie-restricted mice. Proc. Natl. Acad. Sci. USA 2010, 107:7467-7472.
53. Zhou F., Filipeanu C.M., Duvernay M.T., Wu G. Cell-surface targeting of a2-adrenergic receptors-Inhibition by a transport deficient mutant through dimerization. Cell. Signal. 2006, 18:318-327.
54. Zhu X., Wess J. Truncated V2 vasopressin receptors as negative regulators of wild-type V2 receptor function. Biochemistry 1998, 37:15773-15784.